28 December 2017 - Low-cost generic drugs have improved outcomes in patients while saving the health care system more than $1 trillion in the past decade. 

However, the prices of some generic drugs, such as captopril (Capoten) and pyrimethamine (Daraprim), have risen substantially in recent years, threatening these gains. 

Effective competition can ensure low prices of generic drugs, but how much is needed remains an open question.

Read Letter to the Editor of the New England Journal of Medicine